



UNIVERSITÀ DEGLI STUDI
DI MILANO



LEIDS UNIVERSITAIR MEDISCH CENTRUM



**HORIZON 2020 - Marie Skłodowska-Curie
ITN-European Joint Doctorate**



**MOGLYNET-PhD programme in
DRUG DISCOVERY AND
DEVELOPMENT**



Project website: www.moglynet.com

CONTACTS

Secretary@moglynet.com
Tel. +390250314471
Fax +390250314476



This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 675527

MOGLYNET

**PhD programme in
DRUG DISCOVERY AND
DEVELOPMENT
2015-2019**

Scholarship Programme
Promoting Institutional Cooperation
and Mobility for
12 early stage researchers

MISSION of MoGlyNet

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry, supported by other institutions/organizations, join their forces for:

- Creating a common platform of knowledge and language for *12 early stage researchers* (ESR) working in the Drug Discovery and Development area aiming to convey complementary Pharma-skills
- Exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry and regulatory authorities
- Establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on


Doctorate Courses/Schools

- University of Milan: Pharmaceutical Sciences
- University of Milan: Experimental and Clinical Pharmacological Sciences
- University of Aberdeen: Graduate School in Life Sciences and Medicine
- University of Antwerp: Antwerp Doctoral School
- University of Barcelona Doctoral School
- University of Leiden: Graduate School of Leiden University Medical Center

RESEARCH PROJECT

Atherosclerotic cardiovascular disease is the major cause of death in the western world. Thanks to cholesterol-lowering drugs, the lifespan and wellbeing of patients have been significantly improved. **However, a large group of patients does not fully benefit from current lipid-lowering strategies.**

Our multidisciplinary approach is focused on counteracting neovessel formation to prevent plaque rupture and its cardiovascular complications, thus leading to a more effective therapy for atherosclerosis.



Research methodology and approach

The MoGlyNet consortium is strongly multidisciplinary and takes advantage of a number of different state-of-the-art technologies and methodologies:

- Computational chemistry and synthesis
- Bioanalytics and biophysics
- *In vitro* and *in vivo* biological evaluation
- Imaging
- Metabolomic and Proteomic studies
- Oxidative stress studies

Beneficiaries

- University of Milan (Pharmaceutical Sciences and Pharmacological and Biomolecular Sciences Departments), Italy – **Coordinating University**
- University of Aberdeen (Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition), UK
- University of Antwerp (Laboratory of Physiopharmacology), Belgium
- University of Barcelona (Department of Biochemistry and Molecular Biology), Spain
- Leiden University Medical Center (Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine), The Netherlands

Partners and Associations

- Bayer HealthCare Manufacturing S.r.l., Italy
- Biomax Informatics AG, Germany
- HistoGeneX N.V., Belgium
- KemoTech Srl, Italy
- Linkcare Health Services, Spain
- Ingenus Pharmaceutical GmbH, Switzerland
- PPD Italy srl, Italy
- EIPG (European Industrial Pharmacists Group)
- EAS (European Atherosclerosis Society)
- EDQM (European Directorate for the Quality of Medicines)